Serum Marker/Blood Test
Verification of a blood based targeted proteomics signature for malignant pleural mesothelioma
Cancer Epidemiol Biomarkers, July 30, 2020 (Epub ahead of print) [Link] Ferdinando Cerciello, et.al. Abstract Background: We have verified a mass spectrometry (MS) based targeted proteomics signature for the detection of malignant pleural mesothelioma (MPM) from the blood. Methods: A seven-peptide biomarker MPM signature by targeted proteomics in serum was identified in a previous independent…
Read MoreImproved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples – a short report
Cell Oncology 2017 June 2 [Epub ahead of print] [Link] Beije N, Kraan J, den Bakker MA, Maat APWM, van der Leest C, Cornelissen R, Van NM, Martens JWM, Aerts JGJV, Sleijfer S Abstract PURPOSE: There is a lack of robust and clinically utilizable markers for the diagnosis and prognostication of malignant pleural mesothelioma (MPM).…
Read MoreGlycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma
Oncotarget 2016 October 4 [Epub ahead of print] [Link] Schneider MA, Muley T, Kahn NC, Warth A, Thomas M, Herth FJ, Dienemann H, Meister M Abstract Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor with a short survival time arising from the mesothelial cells of the pleura. Soluble mesothelin-related peptide (SMRP), osteopontin or…
Read MoreCombination of onconase and dihydroartemisinin synergistically suppresses growth and angiogenesis of non-small-cell lung carcinoma and malignant mesothelioma
Acta Biochemica et Biophysica Sinica 2016 September 2 [Epub ahead of print] [Link] Shen R, Li J, Ye D, Wang Q, Fei J Abstract Onconase (Onc) is a cytotoxic ribonuclease derived from leopard frog oocytes or early embryos, and has been applied to the treatment of malignant mesothelioma in clinics. Onc also exhibits effective growth…
Read MorePrognostic value of several biomarkers for the patients with malignant pleural mesothelioma
Tumour Biology 2015 September11 [Epub ahead of print] [Link] Liu H, Wu L, Wang W. Abstract Malignant pleural mesothelioma (MPM) is a highly aggressive tumor of the pleura closely related to asbestos exposure. Rare as it is, the incidence of MPM is predicted to increase mainly as a result of a lengthy latency period from…
Read MoreMesothelin in Serum and Pleural Effusion in the Diagnosis of Malignant Pleural Mesothelioma with Non-positive Cytology
Anticancer Research 2014 December [Link] Franceschini MC, Ferro P, Canessa PA, Battolla E, Dessanti P, Valentino A, Casolari L, Fontana V, Pezzi R, Fedeli F, Pistillo MP, Roncella S. Abstract Background/Aim Mesothelin (SMRP) is regarded as a biomarker of malignant pleural mesothelioma (MPM). Herein, we analyzed the contribution of SMRP detection in pleural effusion and…
Read MoreCombination of MiR-103a-3p and Mesothelin Improves the Biomarker Performance of Malignant Mesothelioma Diagnosis
PLoS One 2014 Dec 3 [Link] Weber DG, Casjens S, Johnen G, Bryk O, Raiko I, Pesch B, Kollmeier J, Bauer TT, Brüning T. Abstract Background For the detection of malignant mesothelioma no single biomarker with reasonable sensitivity and specificity has been described so far. Mesothelin, the most prominent blood-based biomarker, is characterized by high…
Read MoreExpression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma
Tumori 2014 Sept-Oct [Link] Comin CE, Novelli L, Cavazza A, Rotellini M, Cianchi F, Messerini L. Abstract Aims and Background A number of immunohistochemical markers have been suggested as useful in the positive diagnosis of epithelioid mesothelioma. The most widely used mesothelioma markers are thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1. Numerous investigations have demonstrated…
Read MoreA serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice
BMC Cancer. 2014 September 17 [Epub ahead of print] [Link] Linch M, Gennatas S, Kazikin S, Iqbal J, Gunapala R, Priest K, Severn J, Norton A, Ayite B, Bhosle J, O Brien M, Popat S. Abstract Background Malignant mesothelioma (MM) carries a poor prognosis and response rates to palliative chemotherapy remain low. Identifying patients with…
Read MoreComparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
Thorax. 2014 July 18. [Epub ahead of print] [Link] Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, Segal A, Bill Musk AW, Lee YC, Skates SJ, Nowak AK, Robinson BW. Abstract Background Pleural malignant mesothelioma (MM) is a deadly tumour predominantly associated with asbestos exposure. A reliable diagnostic and prognostic marker…
Read More